Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sjögren's syndrome

Zhang,Ni; Yang,Ning; Chen,Qilin; Qiu,Feng; Li,Xingfu

doi:10.3892/etm.2014.1981

Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sjögren's syndrome

Authors:
- Ni Zhang
- Ning Yang
- Qilin Chen
- Feng Qiu
- Xingfu Li
View Affiliations

Affiliations: Department of Hematology, Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Center for Oncology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Rheumatology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: September 22, 2014 https://doi.org/10.3892/etm.2014.1981
Pages: 1643-1647

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression and effect of progranulin (PGRN) in patients with primary Sjögren's syndrome (pSS). In total, 26 newly diagnosed pSS patients and 26 healthy subjects were enrolled in this study. The serum levels of PGRN and the inflammatory factor, interleukin‑6 (IL‑6), were detected using ELISA. In addition, the mRNA expression levels of these molecules were detected by quantitative polymerase chain reaction. The serum levels of PGRN and IL‑6 in the pSS patients increased significantly compared with the healthy controls (P<0.05). During the remission stages, the levels of PGRN and IL‑6 were comparable to those of the healthy controls. The serum level of PGRN in the pSS patients was shown to correlate with that of IL‑6 in the pre‑treatment and post‑treatment stages. PGRN was upregulated in the pSS patients, indicating a possible role of PGRN in the pathogenesis and development of pSS.

View Figures

View References

1	Ramos-Casals M, Brito-Zerón P and Font J: The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 36:246–255. 2007.
2	Ramos-Casals M, Tzioufas AG and Font J: Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 64:347–354. 2005.
3	Fox RI, Stern M and Michelson P: Update in Sjögren syndrome. Curr Opin Rheumatol. 12:391–398. 2000.
4	Tang W, Lu Y, Tian QY, et al: The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 332:478–484. 2011. View Article : Google Scholar
5	Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
6	Hrabal R, Chen Z, James S, Bennett HP and Ni F: The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol. 3:747–752. 1996. View Article : Google Scholar : PubMed/NCBI
7	Bateman A and Bennett HP: The granulin gene family: from cancer to dementia. Bioessays. 31:1245–1254. 2009. View Article : Google Scholar : PubMed/NCBI
8	Feng JQ, Guo FJ, Jiang BC, et al: Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB J. 24:1879–1892. 2010. View Article : Google Scholar : PubMed/NCBI
9	Daniel R, He Z, Carmichael KP, Halper J and Bateman A: Cellular localization of gene expression for progranulin. J Histochem Cytochem. 48:999–1009. 2000. View Article : Google Scholar : PubMed/NCBI
10	He Z, Ong CH, Halper J and Bateman A: Progranulin is a mediator of the wound response. Nat Med. 9:225–229. 2003. View Article : Google Scholar
11	Kessenbrock K, Fröhlich L, Sixt M, et al: Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest. 118:2438–2447. 2008.PubMed/NCBI
12	Zhu J, Nathan C, Jin W, et al: Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 111:867–878. 2002. View Article : Google Scholar : PubMed/NCBI
13	Guo F, Lai Y, Tian Q, Lin EA, Kong L and Liu C: Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheum. 62:2023–2036. 2010.PubMed/NCBI
14	Tishler M, Yaron I, Shirazi I, Yossipov Y and Yaron M: Increased salivary interleukin-6 levels in patients with primary Sjögren’s syndrome. Rheumatol Int. 18:125–127. 1999.PubMed/NCBI
15	Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T and Carson DA: B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 167:1253–1258. 1988. View Article : Google Scholar : PubMed/NCBI
16	Naka T, Nishimoto N and Kishimoto T: The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4(Suppl 3): S233–S242. 2002. View Article : Google Scholar : PubMed/NCBI
17	Suzuki H, Yasukawa K, Saito T, Narazaki M, Hasegawa A, Taga T and Kishimoto T: Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol. 23:1078–1082. 1993. View Article : Google Scholar : PubMed/NCBI
18	Tang B, Matsuda T, Akira S, Nagata N, Ikehara S, Hirano T and Kishimoto T: Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol. 3:273–278. 1991. View Article : Google Scholar : PubMed/NCBI
19	Tackey E, Lipsky PE and Illei GG: Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 13:339–343. 2004. View Article : Google Scholar : PubMed/NCBI
20	Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L and Lundberg I: Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 18:565–570. 2000.PubMed/NCBI
21	Eilertsen GØ, Nikolaisen C, Becker-Merok A and Nossent JC: Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus. 20:607–613. 2011.PubMed/NCBI
22	Mihara M, Nishimoto N and Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 5:683–690. 2005. View Article : Google Scholar : PubMed/NCBI